about
A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortalityAre PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trialCombination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic TrialAssociation between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and TenecteRecombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trialAssociation between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial.First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials.Risk of thrombocytopenia with glycoprotein IIb/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials.Complementary prognostic values of ST segment deviation and Thrombolysis In Myocardial Infarction (TIMI) risk score in non-ST elevation acute coronary syndromes: Insights from the Platelet Receptor Inhibition in Ischemic Syndrome Management in PatieLeft atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48.Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.Bridging therapy after recent stent implantation: case report and review of data.One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial.Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In MyocardialRelation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry.Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapyIn patients with acute myocardial infarction, the impact of hyperglycemia as a risk factor for mortality is not homogeneous across age-groups.Low-molecular-weight heparins for the treatment of acute coronary syndromes.Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 YearsThe year in non-ST-segment elevation acute coronary syndromes.High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarctionConcomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial.Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical TrialsPCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.The year in non-ST-segment elevation acute coronary syndrome.Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic SubstudyManagement of ST-elevation myocardial infarction: an update on pharmacoinvasive recanalization.Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trialSudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial.Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion.The year in non-ST-segment elevation acute coronary syndrome.Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.Antithrombotics in acute coronary syndromes.Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients.Management of ST-segment elevation myocardial infarction: Comparison of the updated guidelines from North America and Europe.
P50
Q26747195-353E0617-F154-4D93-9677-F631C6E31410Q28081221-8A76469F-AF71-4A86-B4EE-5E93E061F7B3Q28167073-7FBCCEA8-31B8-4681-B559-E1A5639F293FQ28195722-BE796D39-A7D3-4D61-B177-8C9829651CEFQ28209164-2040C36E-0320-4C05-9142-C7A0D1D4EEE4Q28217795-3F7C925B-98E8-4D3B-A6CA-2804128BED94Q30909780-7C633DEF-70FA-4BF7-ABD1-3D2A3FF4C977Q30983150-61F82D10-6EDB-46A4-A30B-15BED7D70922Q31095333-3C5C4171-378B-4F3F-9643-9B79B81F807AQ33332963-3EBD19BD-C6F4-441C-A3A2-2F38B0D070E4Q33434702-B0E25F2B-9714-49BF-A21F-983A91AC3406Q33595946-FDB156D6-F702-470E-A643-F266556D24B3Q33722721-4BA1955D-02EA-4BA2-B576-A085F370968EQ34043472-7490472A-5896-44A0-9C1C-627A59A7594EQ34054380-FC3AF960-A356-417D-979E-6B700D958EF0Q34110758-EA923911-1142-4873-9F03-61705C194E09Q34479098-577BFA7A-00E6-47CB-AD61-497791D5A888Q34624280-A4470483-A2B1-4A9C-AA1A-489E5E92D9C1Q34631540-EECA9252-D8F8-4DBA-AD88-F2667659857AQ35141471-44F57CC1-98E2-484F-9C21-24755A4DFB21Q35620181-653C2A1E-44EE-4381-B33E-2645CEC6FBE4Q35806411-5C820892-8702-482E-ACD5-23552E932099Q35883044-C8A5FE87-8D45-4842-AD01-6DC17CC26153Q36247560-D2FDED77-7F55-4536-92C0-A2826D875765Q36407135-937C2498-EB1B-4861-BA64-2385BFAC0FD7Q36713982-C13FE4DD-042B-4B9D-961D-CB4D44481B9DQ36869386-C27F3588-B004-4024-81E2-F96CA12554D3Q36930207-81E68778-7090-408B-9247-B3D056EEDFD2Q36954864-F174D767-1816-4559-8828-772024D33496Q36956814-8A9941D3-5F5F-49B6-9CBC-3195A53A5102Q36971088-2CC5A027-9D36-4EAD-A808-984AC51397A8Q37183389-01184777-81AE-4AE1-8796-CA6EAD1FCB96Q37223867-366C4925-4405-4656-824A-20591EDFC608Q37240789-13C1C507-E0E3-428A-B62D-A7171889944EQ37255321-9EF1DD27-90C0-4303-ABE6-5D2F4E201386Q37291568-38B9F6DB-0B5A-436E-9C2C-62936B660C89Q37405863-2A7B9917-BE5E-40AC-981A-572AFE647653Q37591606-DD2C6060-E476-4A0B-A839-9C0053CEB1D2Q37599585-2037703F-198C-49F9-9A1B-A1C9F06F113DQ37620768-6B20B283-E788-42FC-ABC9-4D0F090E06FF
P50
description
researcher ORCID ID = 0000-0003-4110-7675
@en
wetenschapper
@nl
name
Robert P Giugliano
@ast
Robert P Giugliano
@en
Robert P Giugliano
@es
Robert P Giugliano
@nl
type
label
Robert P Giugliano
@ast
Robert P Giugliano
@en
Robert P Giugliano
@es
Robert P Giugliano
@nl
prefLabel
Robert P Giugliano
@ast
Robert P Giugliano
@en
Robert P Giugliano
@es
Robert P Giugliano
@nl
P106
P1153
7005135528
P31
P496
0000-0003-4110-7675